With eyes on FDA nod, Ivenix bags first of $50M for next-gen infusion pump

With its next-gen system, Ivenix aims to solve problems that plague infusion pumps. (Credit: Ivenix)

Ivenix reeled in the first tranche of $50 million in equity, which will support its bid for FDA clearance as well as a personnel expansion for the commercial launch of its infusion pump. The company will pick up the remaining funds when it meets regulatory milestones.

Infusion pumps are used to deliver fluids, including nutrients and drugs, to patients. With its next-generation system, Ivenix aims to tackle a number of issues that can affect these pumps.

Between 2005 and 2009, the FDA reported about 56,000 adverse events, including injuries and deaths, linked to these pumps. While some were caused by user error, the FDA noted that many stemmed from “deficiencies in device design and engineering.” These include software problems, alarm malfunctions and poor user interface design.

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

“A number of factors are fueling investor interest in Ivenix, including the lack of innovation in the market, and the incidence of errors in infusion administration,” Iveni CEO Stuart Randle said in a statement. “Our system represents a complete redesign of the infusion pump from the ground up, with fully integrated technology to support interoperability and improved safety and performance.”

The system comprises a new pump technology and a smartphone-like user interface, as well as an IT system that easily integrates data from the device into a patient’s electronic medical record.

Two new, undisclosed investors led the financing, while existing backers F-Prime Capital Partners and WuXi Healthcare Ventures also participated. Ivenix previously raised $42 million in 2015.

Suggested Articles

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.

Alcon has announced plans to launch its daily disposable contact lens in the U.S. made from a new material.

A mesh of integrated, electric sensors aims to track the earliest stages of tissue development and differentiation.